
Episode 78
Biotech Hangout
00:00
Conflicting Data and Potential Delays for a Radio Pharmaceutical in Prostate Cancer Treatment
This chapter explores Novartis' groundbreaking radio pharmaceutical for prostate cancer, targeting p p sma. It discusses conflicting data on the drug's efficacy, with impressive progression-free survival (PFS) data but currently unfavorable overall survival (OS) data. The speaker anticipates further analysis to unveil the drug's true effectiveness, attributing the discrepancy to patient crossover.
Transcript
Play full episode